Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.
The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S. Food and Drug Administration (FDA) in 2016, and Apadaz® (hydrocodone bitartrate and acetaminophen) tablets. Collegium also markets Rybix® ODT (oxycodone), an orally disintegrating tablet, and has rights to the fentanyl transdermal system ONSOLIS® under a distribution agreement. These products are supported by a dedicated commercial organization and are primarily available in the United States.
Headquartered in Wilmington, North Carolina, Collegium maintains research, development and manufacturing operations, including a facility in Richmond, Virginia. Since its incorporation in 2013, the company has expanded its product portfolio and pursued a pipeline of additional abuse-deterrent drug candidates, seeking to address unmet needs in both acute and chronic pain treatment.
Collegium is led by a management team with experience in specialty pharmaceuticals and regulatory affairs. Michael Thomas serves as President and Chief Executive Officer, guiding the company’s strategic direction and commercial growth initiatives. Under this leadership, Collegium continues to advance its mission of improving patient safety and outcomes through innovative drug delivery technologies.
AI Generated. May Contain Errors.
Free COLL Stock Alerts